Optiray (Ioversol)

Ioversol contains iodine atoms that absorb X‑ray photons, increasing the radiodensity of blood and tissues where it distributes. This heightened attenuation creates a clear contrast between enhanced structures and surrounding anatomy, improving diagnostic image quality.

The dose of Optiray is determined by the prescribing clinician based on the specific imaging study, patient weight, renal function, and the required level of contrast enhancement. Exact dosing regimens are individualized and not standardized.

Optiray should be used during pregnancy or breastfeeding only if the potential diagnostic benefit outweighs the possible risk to the fetus or infant. Clinicians should assess individual circumstances and follow local regulatory guidance.

To order Optiray, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Optiray (Ioversol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. It provides comparable image quality to other modern non‑ionic agents while reducing the incidence of adverse reactions and renal toxicity.

Optiray should be stored at ambient temperature, protected from light and moisture, and kept in its original packaging until use. Avoid freezing or exposing the solution to extreme temperatures to maintain its stability.

Optiray is administered by a trained healthcare professional via intra‑arterial or intravenous injection, typically using a power injector or manual bolus, depending on the imaging protocol and required contrast volume.

The most serious risks include severe allergic reactions (anaphylaxis), contrast‑induced nephropathy, and thyroid dysfunction. Patients with known iodine allergy, impaired renal function, or thyroid disease should be evaluated carefully before administration.

Optiray should be avoided in patients with a documented hypersensitivity to iodinated contrast media, severe renal impairment without adequate hydration, uncontrolled hyperthyroidism, or in those for whom the diagnostic benefit does not justify the potential risk.